1622 related articles for article (PubMed ID: 35856385)
1. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
[TBL] [Abstract][Full Text] [Related]
2. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
[TBL] [Abstract][Full Text] [Related]
5. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
Xiang T; Wang J; Zheng X
Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
[TBL] [Abstract][Full Text] [Related]
6. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.
Chatterjee S; Bhattacharya M; Nag S; Dhama K; Chakraborty C
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680207
[TBL] [Abstract][Full Text] [Related]
7. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
8. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
9. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
10. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
[TBL] [Abstract][Full Text] [Related]
11. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
[TBL] [Abstract][Full Text] [Related]
12. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
[TBL] [Abstract][Full Text] [Related]
13. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
14. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.
Pather S; Madhi SA; Cowling BJ; Moss P; Kamil JP; Ciesek S; Muik A; Türeci Ö
Front Immunol; 2023; 14():1130539. PubMed ID: 37287979
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.
Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X
Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089
[TBL] [Abstract][Full Text] [Related]
17. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD
Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676
[TBL] [Abstract][Full Text] [Related]
18. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
19. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S; Wang L; Zhu Y; Lu L; Jiang S
Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
